Insider Selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells 1,995 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin Klee sold 1,995 shares of the business’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.89, for a total value of $27,710.55. Following the completion of the sale, the chief executive officer directly owned 3,379,398 shares in the company, valued at approximately $46,939,838.22. This represents a 0.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Amylyx Pharmaceuticals Stock Up 15.7%

Amylyx Pharmaceuticals stock traded up $2.25 during mid-day trading on Tuesday, hitting $16.55. 4,418,477 shares of the company were exchanged, compared to its average volume of 1,376,666. The company has a market capitalization of $1.82 billion, a PE ratio of -9.19 and a beta of -0.31. The business has a fifty day moving average of $13.17 and a 200 day moving average of $11.75. Amylyx Pharmaceuticals, Inc. has a 1-year low of $2.60 and a 1-year high of $16.96.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. Research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd bought a new stake in Amylyx Pharmaceuticals during the third quarter worth about $48,000. California State Teachers Retirement System acquired a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $28,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $45,000. BNP Paribas Financial Markets increased its stake in shares of Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after purchasing an additional 5,904 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $47,000. Institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AMLX. Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. Bank of America lifted their price target on shares of Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Citigroup increased their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. HC Wainwright raised their price objective on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Robert W. Baird boosted their price target on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.